Data from: Elovanoids counteract oligomeric β-Amyloid-induced gene expression and protect photoreceptors

Nicolas Bazan, Louisiana State University Health Sciences Center New Orleans
Khanh Do, Louisiana State University Health Sciences Center New Orleans
Marie-Audrey Kautzmann, Louisiana State University Health Sciences Center New Orleans
Bokkyoo Jun, Louisiana State University Health Sciences Center New Orleans
William Gordon, Louisiana State University Health Sciences Center New Orleans
Robert Nshimiyimana, Louisiana State University Health Sciences Center New Orleans
Rong Yang, University of Southern California
Nicos Petasis, University of Southern California

Funding

National Institutes of Health - National Eye Institute, Award: R01 EY005121

Eye Ear Nose & Throat Foundation

Abstract

The onset of neurodegenerative diseases activates inflammation that leads to progressive neuronal cell death and impairments in cognition (Alzheimer’s disease, AD) and sight (age-related macular degeneration, AMD). How neuroinflammation can be counteracted is not known. In AMD, amyloid β-peptide (Aβ) accumulates in subretinal drusen. In the 5xFAD retina, we found early functional deficiencies (ERG) without photoreceptor cell (PRC) death and identified early insufficiency in biosynthetic pathways of pro-homeostatic/neuroprotective mediators, neuroprotectin D1 (NPD1) and elovanoids (ELVs). To mimic an inflammatory milieu in wild-type (WT) mouse, we triggered retinal pigment epithelium (RPE) damage/PRC death by subretinally injected oligomeric β-Amyloid (OAβ) and observed that ELVs administration counteracted their effects, protecting these cells. In addition, ELVs prevented OAβ-induced changes in gene expression engaged in senescence, inflammation, autophagy, extracellular matrix remodeling and AMD. Moreover, since OAβ target the RPE, we used primary human RPE cell cultures and demonstrated that OAβ caused cell damage, while ELVs protected and restored gene expression as in mouse. Our data show OAβ activates senescence as reflected by enhanced expression of p16INK4a, MMP1, p53, p21, p27 and Il-6 and of senescence-associated secretory phenotype (SASP) secretome, followed by RPE and PRC demise and that elovanoids 32 and 34 blunt these events and elicits protection. In addition, ELVs counteracted OAβ-induced expression of genes engaged in AMD, autophagy and extracellular matrix (ECM) remodeling. Overall, our data uncovered that ELVs downplay OAβ-senescence program induction and inflammatory transcriptional events and protect RPE cells and PRC, and therefore have potential as a possible therapeutic avenue for AMD.